A new study published in the journal of PloS One showed that although reoperative therapy with evolocumab with rosuvastatin ...

A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...

- Reduced inflammation at the site of myocardial infarction and improved heart function demonstrated. Novel therapy to modulate immune response with apoptotic cell-derived nanovesicles. Myocardial ...

The world's first clinical trial to test glenzocimab as a potential new drug to improve the long-term outcomes for heart attack patients will take place in the UK. Glenzocimab is a humanised ...

ST-segment myocardial infarction (STEMI) causes significant morbidity and mortality, with infarct size being the primary predictor of clinical outcome. Given imaging evidence that early IV metoprolol ...

Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide, primarily resulting from an abrupt coronary artery occlusion that deprives myocardial tissue of oxygen.

Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...

MULHOUSE, France, and SUNNYVALE, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc.

ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, ...

Advanced CKD was linked to a higher likelihood of both fatal and non-fatal adverse outcomes after acute myocardial infarction treatment. Patients with advanced chronic kidney disease (ACKD) with acute ...

Treatment with denosumab vs oral bisphosphonates was associated with increased risks for MACE and hypocalcemia in dialysis-dependent patients with osteoporosis.